Condition
Relapsed/Refractory Follicular Lymphoma clinical trials and research
As of November 12, 2026, Find a Trial lists 3 Relapsed/Refractory Follicular Lymphoma clinical trials that are recruiting, at sites in 19 countries (most in Italy (2), China (1), Australia (1)). By phase: Phase 2 (1), Phase 3 (1). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 3Clinical trials
- 19Countries
Newest Relapsed/Refractory Follicular Lymphoma clinical trials
| Study | Phase | Where | Status | Registered |
|---|---|---|---|---|
| Zanubrutinib, rituximab, lenalidomide plus tislelizumab for relapsed/refractory follicular lymphoma | Phase 2 | Nanjing, Jiangsu | Recruiting | Feb 18, 2026 |
| Mosunetuzumab for adults with relapsed/refractory follicular lymphoma after at least two prior therapies (compassionate use) | — | Milan | Recruiting | Dec 12, 2025 |
| Testing a new drug combination for relapsed or refractory follicular and marginal zone lymphoma | Phase 3 | Los Angeles, California and 170 other locations | Recruiting | Nov 28, 2023 |
All recruiting trials (3)
-
Zanubrutinib, rituximab, lenalidomide plus tislelizumab for relapsed/refractory follicular lymphoma
This trial tests whether adding the PD‑1 blocker tislelizumab to zanubrutinib, rituximab, and lenalidomide helps adults with relapsed or refractory follicular lymphoma who have had at least two prior therapies.
-
Mosunetuzumab for adults with relapsed/refractory follicular lymphoma after at least two prior therapies (compassionate use)
This project will see if the antibody drug mosunetuzumab helps adults with follicular lymphoma that has come back or stopped responding after at least two prior treatments when given through a compassionate use program.
-
Testing a new drug combination for relapsed or refractory follicular and marginal zone lymphoma
This study is testing a new combination of drugs to see if it can help adults with relapsed or hard-to-treat follicular or marginal zone lymphoma feel better compared to standard treatment.
Related topics
Quick answers
How many Relapsed/Refractory Follicular Lymphoma clinical trials are recruiting right now?
3, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.
Where are these trials running?
In 19 countries. The most sites are in Italy (2 trials), China (1 trial), Australia (1 trial), Austria (1 trial), Belgium (1 trial). Each study page lists its sites and which ones are recruiting.
What phases are they in?
Phase 2: 1, Phase 3: 1. Trials with no phase listed are usually device, behavioural or observational studies.
How do I join one?
Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.